Robert W. Duggan
Known title: DirectorCIK: 0001055919
Robert W. Duggan's purchase track record
How the stock did after each of Robert W. Duggan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
11
of 14 since August 16, 2022
Stock higher 6 months later
64%
3 months: 71%
Median 6-month return
+27.6%
3 months: +5.6%
Beat the S&P 500
64%
median +10.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/12/2026 | SMMT | $49.99M | +25.3% | pending | — |
| 6/4/2026 | SMMT | $1.46M | +15.4% | pending | — |
| 5/11/2026 | PLSE | $13.00M | +117.6% | pending | — |
| 10/21/2025 | SMMT | $500K | -14.3% | +40.8% | +4.9% |
| 9/10/2025 | SMMT | $5.98M | +1.9% | -8.7% | +3.7% |
| 9/10/2025 | PLSE | $508K | -3.9% | +35.5% | +3.7% |
| 12/11/2024 | PLSE | $2.70M | -0.8% | -3.1% | -1.0% |
| 9/11/2024 | PLSE | $2.28M | +0.8% | -0.1% | +0.8% |
| 12/6/2023 | PLSE | $3.56M | +3.3% | +52.2% | +17.7% |
| 11/28/2023 | PLSE | $5.86M | +24.5% | +52.4% | +16.5% |
| 11/17/2023 | PLSE | $123K | +50.0% | +27.6% | +17.5% |
| 5/9/2023 | PLSE | $65.25M | -9.3% | -34.0% | +6.3% |
| 3/6/2023 | SMMT | $395.31M | +33.8% | +13.0% | +11.1% |
| 8/16/2022 | SMMT | $92.00M | +7.9% | +105.9% | -3.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Transaction History
| SMMT | ▲ Buy | Open Market | 3,810,000 | $50.0M | 6/12/2026 | View on chart |
| SMMT | ▲ Buy | Open Market | 100,000 | $1.5M | 6/4/2026 | View on chart |
| PLSE | ▲ Buy | Open Market | 660,233 | $13.0M | 5/11/2026 | View on chart |
| SMMT | ▲ Buy | Grant | 13,980,789 | $262.0M | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Grant | 266,808 | $5.0M | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Open Market | 26,680 | $500K | 10/21/2025 | View on chart |
| SMMT | ▲ Buy | Open Market | 5,000 | $90K | 9/11/2025 | View on chart |
| SMMT | ▲ Buy | Open Market | 333,394 | $5.9M | 9/10/2025 | View on chart |
| PLSE | ▲ Buy | Open Market | 34,659 | $508K | 9/10/2025 | View on chart |
| SMMT | ▲ Buy | Option Exercise | 74,545 | $197K | 5/30/2025 | View on chart |
| SMMT | ▼ Sell | Other | 3,985,055 | $6.3M | 4/8/2025 | View on chart |
| PLSE | ▼ Sell | Other | 49,312 | $542K | 12/18/2024 | View on chart |
| PLSE | ▼ Sell | Other | 5,187,824 | $57.1M | 12/18/2024 | View on chart |
| PLSE | ▼ Sell | Other | 69,020 | $759K | 12/18/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 55,256 | $949K | 12/13/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 45,404 | $778K | 12/12/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 6,054 | $101K | 12/11/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 50,000 | $871K | 12/11/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 145,140 | $2.1M | 9/12/2024 | View on chart |
| SMMT | ▲ Buy | Grant | 3,325,991 | $75.5M | 9/11/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 12,800 | $189K | 9/11/2024 | View on chart |
| PLSE | ▼ Sell | Other | 69,020 | — | 7/3/2024 | View on chart |
| PLSE | ▼ Sell | Other | 5,187,824 | — | 7/3/2024 | View on chart |
| PLSE | ▼ Sell | Other | 49,312 | — | 7/3/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 17,999 | $165K | 12/12/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 90,118 | $844K | 12/11/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 116,656 | $1.1M | 12/8/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 74,852 | $688K | 12/7/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 82,813 | $750K | 12/6/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 9,933 | $59K | 12/6/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 66,021 | $617K | 12/5/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,000 | $213K | 12/4/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 20,347 | $217K | 12/4/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 27,000 | $280K | 12/4/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 45,600 | $414K | 12/1/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 152,944 | $1.4M | 11/30/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 1,667 | $10K | 11/29/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 158,600 | $1.5M | 11/29/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 60,000 | $553K | 11/29/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 124,397 | $1.1M | 11/28/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 241 | $1K | 11/17/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 10,000 | $61K | 11/17/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 10,000 | $61K | 11/17/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 3,333 | $20K | 11/7/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 9,932 | $59K | 11/7/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 1,667 | $10K | 8/25/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 1,667 | $10K | 7/25/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 1,666 | $10K | 7/7/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 65,467 | $140K | 7/7/2023 | View on chart |
| PLSE | ▲ Buy | Option Exercise | 65,000 | $139K | 7/5/2023 | View on chart |
| PLSE | ▼ Sell | Other | 5,683,163 | $11.7M | 6/14/2023 | View on chart |
| PLSE | ▼ Sell | Other | 81,025 | $166K | 6/14/2023 | View on chart |
| PLSE | ▲ Buy | Open Market | 10,022,937 | $65.2M | 5/9/2023 | View on chart |
| SMMT | ▲ Buy | Open Market | 376,489,880 | $395.3M | 3/6/2023 | View on chart |
| SMMT | ▼ Sell | Other | 9,346,434 | — | 12/6/2022 | View on chart |
| SMMT | ▲ Buy | Open Market | 94,849,203 | $92.0M | 8/16/2022 | View on chart |
| PLSE | ▼ Sell | Other | 81,025 | — | 6/9/2022 | View on chart |
| PLSE | ▼ Sell | Other | 5,683,163 | — | 6/9/2022 | View on chart |
| SMMT | ▼ Sell | Other | 21,135 | — | 5/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo
Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.